Next Article in Journal
MicroRNA Polymorphisms in Cancer: A Literature Analysis
Next Article in Special Issue
Deficiency of iPLA2β Primes Immune Cells for Proinflammation: Potential Involvement in Age-Related Mesenteric Lymph Node Lymphoma
Previous Article in Journal
Targeting RTK Signaling Pathways in Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2015, 7(3), 1785-1805; doi:10.3390/cancers7030861

Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge

1
Department of Biochemistry, Osmania University, Hyderabad, Telangana 500007, India
2
Department of Surgery, University of Florida, 1600 SW Archer Rd, Rm 6175, P.O. Box 100109, Gainesville, FL 32610, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Gabriele Multhoff
Received: 11 June 2015 / Revised: 7 August 2015 / Accepted: 17 August 2015 / Published: 3 September 2015
(This article belongs to the Special Issue Stress Responses in Tumors and The Tumor Microenvironment)
View Full-Text   |   Download PDF [612 KB, uploaded 3 September 2015]   |  

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and incidence rates are rising. Both detection and treatment options for pancreatic cancer are limited, providing a less than 5% five-year survival advantage. The need for new biomarkers for early detection and treatment of pancreatic cancer demands the efficient translation of bench knowledge to provide clinical benefit. One source of therapeutic resistance is the pancreatic tumor microenvironment, which is characterized by desmoplasia and hypoxia making it less conducive to current therapies. A major factor regulating desmoplasia and subsequently promoting chemoresistance in pancreatic cancer is hepatocyte growth factor (HGF), the sole ligand for c-MET (mesenchymal-epithelial transition), an epithelial tyrosine kinase receptor. Binding of HGF to c-MET leads to receptor dimerization and autophosphorylation resulting in the activation of multiple cellular processes that support cancer progression. Inhibiting activation of c-MET in cancer cells, in combination with other approaches for reducing desmoplasia in the tumor microenvironment, might significantly improve the success of chemotherapy. Therefore, HGF makes a potent novel target for developing therapeutic strategies in combination with existing drugs for treating pancreatic adenocarcinoma. This review provides a comprehensive analysis of HGF and its promising potential as a chemotherapeutic target for pancreatic cancer. View Full-Text
Keywords: pancreatic cancer; HGF; desmoplasia; hypoxia; acidosis; chemotherapy pancreatic cancer; HGF; desmoplasia; hypoxia; acidosis; chemotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rizwani, W.; Allen, A.E.; Trevino, J.G. Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. Cancers 2015, 7, 1785-1805.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top